You are here: Industry Insights > Regeneron

News List

FDA limits usage of Lilly and Regeneron’s monoclonal antibodies for Covid-19 Pharmaceutical-Technology
January 26, 2022
The move comes after data showed these therapies are highly unlikely to be active against the Omicron variant.
FDA Halts Use of Regeneron, Lilly COVID Antibody Therapies contractpharma
January 25, 2022
Cites the therapies are less able to target Omicron because of its mutations.
Vaccibody rebrands to Nykode and bags $925m deal with Regeneron Pharmaceutical-Technology
November 25, 2021
Norwegian vaccine and immunotherapy-focused biopharma Nykode Therapeutics started off in 2007 as Vaccibody, before rebranding this week to signal its significant growth and transformation plans.
Nykode Therapeutics partners with Regeneron to develop cancer and infectious disease vaccines PharmaTimes
November 24, 2021
Nykode Therapeutics, a clinical-stage biopharmaceutical company, announced that it has entered into a collaboration agreement with Regeneron.
Libtayo? with chemotherapy trial stopped early due to success europeanpharmaceuticalreview
August 10, 2021
Phase III trial of Libtayo? (cemiplimab) combined with chemotherapy stops early due to significant improvement in overall survival in lung cancer patients.
Sanofi and Regeneron’s Libtayo trial stops early due to survival improvement pharmatimes
August 09, 2021
A Phase III trial of Sanofi and Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) in combination with platinum-doublet chemotherapy has been stopped early after meeting its overall survival (OS) primary endpoint in patients with advanced non-small cell ...
Ocular Therapeutix Announces Termination of the Collaboration with Regeneron to Develop a Sustained-Release Formulation of Aflibercept for the Treatment of Wet AMD and other Serious Retinal Diseases firstwordpharma
August 06, 2021
Ocular Therapeutix, Inc. (NASDAQ:OCUL) today announced that Regeneron has terminated the option and license agreement collaboration between the companies.
FDA grants EUA for Regeneron’s antibody cocktail to prevent Covid-19 pharmaceutical-technology
August 02, 2021
The US Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for Regeneron Pharmaceuticals’ investigational antibody cocktail, REGEN-COV (casirivimab and imdevimab) to prevent Covid-19.
Sanofi, Regeneron’s Dupixent wins positive results in chronic spontaneous urticaria pharmatimes
July 30, 2021
Sanofi and Regeneron’s interleukin-4 (IL-4) and interleukin-13 (IL-13) inhibitor Dupixent has demonstrated positive pivotal results in chronic spontaneous urticaria (CSU) – a chronic inflammatory skin disease.
Regeneron Investing Nearly $2B in Tarrytown, NY Campus contractpharma
July 30, 2021
New York's largest biotech company creating an additional 1,000 jobs over five years.